Back to results
US 2017/0362327 A1Published application
Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain
AssigneeGlenmark Pharmaceuticals S.A.
InventorsAdrian WALMSLEY, Sachin Kumar DUBEY
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies.
Claims10
A humanized anti-TrkA antibody or fragment thereof that bind to human TrkA, wherein said anti-TrkA antibody or fragment thereof comprising heavy chain variable domain CDRs 1, 2 and 3 and light chain variable domain CDRs 1, 2 and 3, and the heavy chain variable domain comprises a sequence selected from the group consisting of SEQ ID NOs:
- 1-5, and the light chain variable domain comprises a sequence selected from the group consisting of SEQ ID NOs:
- 6-13,
- wherein the non-CDR region of the heavy chain variable domain comprise an amino acid substitution at an amino acid position selected from the group consisting of 37, 42, and 89, wherein the amino acid position of each group member is indicated utilizing the numbering system set forth in Kabat for treating bone associated pain.
Dependencies are inferred from the claim text.